Stem Cell Hemostemix Inc. is pleased to announce that it has obtained a patent from the European Union under the title “Regulation of Stem Cells.” Issuing this patent in the European Union is important because it provides verification in multiple countries. In addition, since the European stem cell market is one of the fastest growing markets in the world, EU patents are very important. According to a report entitled “European Stem Cell Market Growth, Trends and Forecasts (2016-2021)”, the market is currently valued at US$4.2 billion and is expected to grow at a compound annual growth rate of 15.7%.
Hemostemix (TSX V: HEM) is a marketed clinical stage biotechnology company focusing on the development and commercialization of proprietary autologous cell therapies to treat ischemic diseases.
Hemostemix’s proprietary platform technology is based on more than 10 years of clinical data, proving that our autologous cell products can regenerate diseased and damaged tissues. An efficient, scalable, and cost-effective platform has the potential to produce treatments for a wide range of ischemic diseases.
The main candidate in the clinical stage, ACP-01, is an autologous cell therapy for the treatment of severe limb ischemia. ACP-01 is currently undergoing phase 2 clinical trials in Canada and the United States.